Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

References

• Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, . Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res 2000;60:4033–6.
   PubMed Web of Science ®Google Scholar
• Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, . Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004–10.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, . Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420–30.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, . Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002; 8:1085–91.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 2007;13:920–8.
   PubMed Web of Science ®Google Scholar
• Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;163:2139–48.
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, . Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128–35.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, . Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483–8.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, . High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207–13.
   PubMed Web of Science ®Google Scholar
• Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 2009.
   Google Scholar
• Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, . Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005;27:49–57.
   PubMed Web of Science ®Google Scholar
• Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, . Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61–6.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218–24.
   PubMed Web of Science ®Google Scholar
• Königsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, . Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods. Cancer Lett 2010;293:117–23.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229–35.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, . Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367–74.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736–50.
   PubMed Web of Science ®Google Scholar
• Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, . Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421–8.
   PubMed Web of Science ®Google Scholar
• Kubista E, Planellas Gomez JV, Dowsett M, Foidart JM, Pohlodek K, . Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: Results from STEM trial. Clin Cancer Res 2007;13:4185–90.
   PubMed Web of Science ®Google Scholar
• Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, . Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 2003;78:97–103.
   PubMed Web of Science ®Google Scholar
• Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47: 2883–91.
   PubMed Web of Science ®Google Scholar
• Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, . Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185:427–34.
   PubMed Web of Science ®Google Scholar
• Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, . Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2010.
   Google Scholar
• Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, . Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010.
   Google Scholar
• Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
   PubMed Web of Science ®Google Scholar
• Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: Proof of concept. Cytometry B Clin Cytom 2010.
   Google Scholar